UCB, Vectura to develop respiratory biologic

UCB Group (Euronext:UCB) and Vectura Group plc (LSE:VEC) partnered to develop a dry powder immunomodulatory biologic to treat severe inflammatory respiratory disease. The partners will jointly manage a program to develop a UCB-generated biological therapy targeting an undisclosed molecule in the immune system to clinical proof of concept. UCB will conduct bioprocess and preclinical development and Vectura will be responsible for clinical development. The companies, which could not be reached for details, did not disclose financial terms. ...